Cyclerion Email Format
Biotechnology ResearchMassachusetts, United States2-10 Employees
Cyclerion is a biotechnology research company based in Cambridge, Massachusetts. Its portfolio centers on clinical-stage and research-stage assets, including praliciguat and olinciguat, with praliciguat being developed for rare kidney disease under an exclusive license to Akebia, and olinciguat targeted for cardiovascular diseases either developed in-house or out-licensed. The firm also holds equity in Tisento Therapeutics and is exploring additional activities such as collaborations, licenses, mergers, acquisitions, and targeted investments aimed at shareholder value. The company operates within the biotechnology research sector, focusing on sGC stimulators with the potential to address kidney and cardiovascular conditions, while evaluating opportunities arising from its asset portfolio and partnerships. Cyclerion is pursuing strategic moves, including a recent merger activity with Korsana Biosciences, which could affect its corporate structure and ownership dynamics moving forward.